Ascletis’ not-so-great weight loss data; Vivace’s $35M Series Dnews2025-03-12T14:22:46+00:00March 12th, 2025|Endpoints News|
Mineralys aims to raise $250M; Coherus discloses layoffsnews2025-03-11T15:07:51+00:00March 11th, 2025|Endpoints News|
CytomX, Amgen pass on T cell engager; Molecular Partners ends work with Novartisnews2025-03-07T15:05:53+00:00March 7th, 2025|Endpoints News|
Corrected: Merck KGaA’s mixed Phase 2 lupus results; Zymeworks pauses work on ADCnews2025-03-06T15:28:51+00:00March 6th, 2025|Endpoints News|
Bristol Myers’ MyoKardia unit ends work with Fulcrum; ALX discloses layoffsnews2025-03-05T15:13:29+00:00March 5th, 2025|Endpoints News|
Tenaya raises about $53M; BeiGene’s PD-1 gets a first-line approvalnews2025-03-04T15:06:32+00:00March 4th, 2025|Endpoints News|
Genentech’s TNKase gets new approval; Sanofi gives up rights to oncology candidatenews2025-03-03T15:46:29+00:00March 3rd, 2025|Endpoints News|
Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeuticsnews2025-02-28T15:13:45+00:00February 28th, 2025|Endpoints News|
Hansoh ends collaboration with Silence; Vir hunts for HBV drug partnernews2025-02-27T15:09:04+00:00February 27th, 2025|Endpoints News|
Harbour BioMed inks deal up to $395M; ORIC refines plans for two drugsnews2025-02-26T15:29:08+00:00February 26th, 2025|Endpoints News|
